Anthony J Kanelidis1, Courtney Premer1, Juan Lopez1, Wayne Balkan1, Joshua M Hare2. 1. From the Interdisciplinary Stem Cell Institute (A.J.K., C.P., W.B., J.M.H.), Department of Molecular and Cellular Pharmacology (C.P.), and Department of Medicine (W.B., J.M.H.), University of Miami Miller School of Medicine, FL; and Florida International University Herbert Wertheim College of Medicine, Miami (J.L.). 2. From the Interdisciplinary Stem Cell Institute (A.J.K., C.P., W.B., J.M.H.), Department of Molecular and Cellular Pharmacology (C.P.), and Department of Medicine (W.B., J.M.H.), University of Miami Miller School of Medicine, FL; and Florida International University Herbert Wertheim College of Medicine, Miami (J.L.). jhare@med.miami.edu.
Abstract
RATIONALE: Accumulating data support a therapeutic role for mesenchymal stem cell (MSC) therapy; however, there is no consensus on the optimal route of delivery. OBJECTIVE: We tested the hypothesis that the route of MSC delivery influences the reduction in infarct size and improvement in left ventricular ejection fraction (LVEF). METHODS AND RESULTS: We performed a meta-analysis investigating the effect of MSC therapy in acute myocardial infarction (AMI) and chronic ischemic cardiomyopathy preclinical studies (58 studies; n=1165 mouse, rat, swine) which revealed a reduction in infarct size and improvement of LVEF in all animal models. Route of delivery was analyzed in AMI swine studies and clinical trials (6 clinical trials; n=334 patients). In AMI swine studies, transendocardial stem cell injection reduced infarct size (n=49, 9.4% reduction; 95% confidence interval, -15.9 to -3.0), whereas direct intramyocardial injection, intravenous infusion, and intracoronary infusion indicated no improvement. Similarly, transendocardial stem cell injection improved LVEF (n=65, 9.1% increase; 95% confidence interval, 3.7 to 14.5), as did direct intramyocardial injection and intravenous infusion, whereas intracoronary infusion demonstrated no improvement. In humans, changes of LVEF paralleled these results, with transendocardial stem cell injection improving LVEF (n=46, 7.0% increase; 95% confidence interval, 2.7 to 11.3), as did intravenous infusion, but again intracoronary infusion demonstrating no improvement. CONCLUSIONS: MSC therapy improves cardiac function in animal models of both AMI and chronic ischemic cardiomyopathy. The route of delivery seems to play a role in modulating the efficacy of MSC therapy in AMI swine studies and clinical trials, suggesting the superiority of transendocardial stem cell injection because of its reduction in infarct size and improvement of LVEF, which has important implications for the design of future studies.
RATIONALE: Accumulating data support a therapeutic role for mesenchymal stem cell (MSC) therapy; however, there is no consensus on the optimal route of delivery. OBJECTIVE: We tested the hypothesis that the route of MSC delivery influences the reduction in infarct size and improvement in left ventricular ejection fraction (LVEF). METHODS AND RESULTS: We performed a meta-analysis investigating the effect of MSC therapy in acute myocardial infarction (AMI) and chronic ischemic cardiomyopathy preclinical studies (58 studies; n=1165 mouse, rat, swine) which revealed a reduction in infarct size and improvement of LVEF in all animal models. Route of delivery was analyzed in AMI swine studies and clinical trials (6 clinical trials; n=334 patients). In AMI swine studies, transendocardial stem cell injection reduced infarct size (n=49, 9.4% reduction; 95% confidence interval, -15.9 to -3.0), whereas direct intramyocardial injection, intravenous infusion, and intracoronary infusion indicated no improvement. Similarly, transendocardial stem cell injection improved LVEF (n=65, 9.1% increase; 95% confidence interval, 3.7 to 14.5), as did direct intramyocardial injection and intravenous infusion, whereas intracoronary infusion demonstrated no improvement. In humans, changes of LVEF paralleled these results, with transendocardial stem cell injection improving LVEF (n=46, 7.0% increase; 95% confidence interval, 2.7 to 11.3), as did intravenous infusion, but again intracoronary infusion demonstrating no improvement. CONCLUSIONS: MSC therapy improves cardiac function in animal models of both AMI and chronic ischemic cardiomyopathy. The route of delivery seems to play a role in modulating the efficacy of MSC therapy in AMI swine studies and clinical trials, suggesting the superiority of transendocardial stem cell injection because of its reduction in infarct size and improvement of LVEF, which has important implications for the design of future studies.
Authors: Lian R Gao; Xue T Pei; Qing A Ding; Yu Chen; Ning K Zhang; Hai Y Chen; Zhi G Wang; Yun F Wang; Zhi M Zhu; Tian C Li; Hui L Liu; Zi C Tong; Yong Yang; Xue Nan; Feng Guo; Jian L Shen; Yan H Shen; Jian J Zhang; Yu X Fei; Hong T Xu; Li H Wang; Hai T Tian; Da Q Liu; Ye Yang Journal: Int J Cardiol Date: 2013-05-04 Impact factor: 4.164
Authors: Konstantinos E Hatzistergos; Henry Quevedo; Behzad N Oskouei; Qinghua Hu; Gary S Feigenbaum; Irene S Margitich; Ramesh Mazhari; Andrew J Boyle; Juan P Zambrano; Jose E Rodriguez; Raul Dulce; Pradip M Pattany; David Valdes; Concepcion Revilla; Alan W Heldman; Ian McNiece; Joshua M Hare Journal: Circ Res Date: 2010-07-29 Impact factor: 17.367
Authors: Anita A Kelkar; Javed Butler; Erik B Schelbert; Stephen J Greene; Arshed A Quyyumi; Robert O Bonow; Ira Cohen; Mihai Gheorghiade; Michael J Lipinski; Wei Sun; Dror Luger; Stephen E Epstein Journal: J Am Coll Cardiol Date: 2015-11-03 Impact factor: 24.094
Authors: Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman Journal: J Am Coll Cardiol Date: 2009-12-08 Impact factor: 24.094
Authors: Alan W Heldman; Darcy L DiFede; Joel E Fishman; Juan P Zambrano; Barry H Trachtenberg; Vasileios Karantalis; Muzammil Mushtaq; Adam R Williams; Viky Y Suncion; Ian K McNiece; Eduard Ghersin; Victor Soto; Gustavo Lopera; Roberto Miki; Howard Willens; Robert Hendel; Raul Mitrani; Pradip Pattany; Gary Feigenbaum; Behzad Oskouei; John Byrnes; Maureen H Lowery; Julio Sierra; Mariesty V Pujol; Cindy Delgado; Phillip J Gonzalez; Jose E Rodriguez; Luiza Lima Bagno; Didier Rouy; Peter Altman; Cheryl Wong Po Foo; Jose da Silva; Erica Anderson; Richard Schwarz; Adam Mendizabal; Joshua M Hare Journal: JAMA Date: 2014-01-01 Impact factor: 56.272
Authors: Adam R Williams; Viky Y Suncion; Frederic McCall; Danny Guerra; Jacques Mather; Juan P Zambrano; Alan W Heldman; Joshua M Hare Journal: J Am Heart Assoc Date: 2013-05-17 Impact factor: 5.501
Authors: Jun-Won Lee; Seung-Hwan Lee; Young-Jin Youn; Min-Soo Ahn; Jang-Young Kim; Byung-Su Yoo; Junghan Yoon; Woocheol Kwon; In-Soo Hong; Kyounghoon Lee; Jun Kwan; Keum Soo Park; Donghoon Choi; Yang Soo Jang; Mun K Hong Journal: J Korean Med Sci Date: 2013-12-26 Impact factor: 2.153
Authors: T I G van der Spoel; W A Gathier; S Koudstaal; F van Slochteren; S Jansen Of Lorkeers; J P G Sluijter; I E Hoefer; P Steendijk; M J M Cramer; P A Doevendans; E van Belle; S A J Chamuleau Journal: J Cardiovasc Transl Res Date: 2015-09-17 Impact factor: 4.132
Authors: Evelyn Kendall Williams; José R García; Robert G Mannino; Rebecca S Schneider; Wilbur A Lam; Andrés J García Journal: Integr Biol (Camb) Date: 2019-04-01 Impact factor: 2.192
Authors: Bryon A Tompkins; Wayne Balkan; Johannes Winkler; Mariann Gyöngyösi; Georg Goliasch; Francisco Fernández-Avilés; Joshua M Hare Journal: Circ Res Date: 2018-03-30 Impact factor: 17.367
Authors: Roberto Bolli; Joshua M Hare; Timothy D Henry; Carrie G Lenneman; Keith L March; Kathy Miller; Carl J Pepine; Emerson C Perin; Jay H Traverse; James T Willerson; Phillip C Yang; Adrian P Gee; João A Lima; Lem Moyé; Rachel W Vojvodic; Shelly L Sayre; Judy Bettencourt; Michelle Cohen; Ray F Ebert; Robert D Simari Journal: Am Heart J Date: 2018-04-04 Impact factor: 4.749
Authors: Dina Rady; Marwa M S Abbass; Aiah A El-Rashidy; Sara El Moshy; Israa Ahmed Radwan; Christof E Dörfer; Karim M Fawzy El-Sayed Journal: Stem Cells Int Date: 2020-08-11 Impact factor: 5.443
Authors: Dan Yang; Connor Galen O'Brien; Gentaro Ikeda; Jay H Traverse; Doris A Taylor; Timothy D Henry; Roberto Bolli; Phillip C Yang Journal: Am Heart J Date: 2019-11-11 Impact factor: 4.749